End 340B, Commentary in New England Journal of Medicine Suggests

NEJM
Policymakers should consider disbanding the 340B program, a student and a professor at the Stanford University School of Medicine say in the New England Journal of Medicine.

Policymakers should consider disbanding the 340B program “given its negative reverberations for patients and markets,” a student and a professor at the Stanford University School of Medicine wrote in a commentary in the latest edition of the New

Read More »

Hospital Groups and Brand Drug Industry React to Wall Street Journal’s 340B Hospital Investigation

WSJ
340B hospitals defended themselves and the program in the wake of a highly critical Wall Street Journal investigation, while the drug industry said the story revealed “abuse that policymakers can no longer ignore.”

Groups that represent 340B hospitals are defending the drug discount program and their role in it in response to a Wall Street Journal article Tuesday that raised questions about how some hospitals qualify for and use the program.

Read More »

Private Oncologist Group-Funded Study Models Effects of Using CMS’s Controversial 2020 340B Hospital Drug Cost Survey

Avalere
A new study models what would happened in 2023 if Medicare paid 340B hospitals for physician administered drugs based on a survey of those hospitals’ drug acquisition costs taken during the COVID pandemic’s darkest days in 2020.

Private practice oncologists have paid for a study to model what would happened in 2023 if Medicare paid 340B hospitals for physician administered drugs based on a survey of those hospitals’ drug acquisition costs taken during the COVID

Read More »

Breaking News

Wall Street Journal Says Its Investigation of 340B Hospitals Raises Questions about Program’s Growth and Purpose

The Wall Street Journal's long article today about hospital participation in 340B comes three months after a similar lengthy critique by The New York Times.

A growing number of hospitals that do not qualify for 340B drug discounts as disproportionate share hospitals are enrolling instead under less demanding criteria for rural referral centers—including nationally prominent urban hospitals in metro Boston, Chicago, and Cleveland,

Read More »

340B Hospitals’ Share of Part B Drug Administration Continues Rising, PhRMA-Funded Study Finds

Infusion
New drug industry-funded research found that Part B drug administration continues rising at 340B hospitals and falling at other hospitals and physician offices.

Thirty-five percent of drugs paid for by Medicare Part B in 2021 were administered in 340B hospital outpatient departments, up from 19% in 2012, new research funded by brand drug manufacturers shows.

The share of Part B drugs

Read More »

U.S. Retail Drug Spending Rose 7.8% in 2021, as COVID Eased and Patients Got Care They Postponed

Drug spending
Retail prescription drug spending rose by 7.8% in 2021, as COVID-19 eased and patients got care they had been putting off, CMS says.

Retail prescription drug spending in the U.S. shot up 7.8% to $378 billion in 2021, more than double the 3.7% spending growth rate in 2020, as the easing of the COVID-19 pandemic brought a surge in doctor visits

Read More »

Extent of 340B’s Impact on Overall Drug Prices Unclear Due to Lack of Data, Study Finds

Leavitt
Lack of data makes it hard to assess 340B's impact on drug company launch prices and covered entities' uses of 340B savings, researchers at consulting firm Leavitt Partners say.

Lack of data makes it hard to assess the 340B program’s overall impact on drug prices charged by pharmaceutical companies and covered entities, a new study by healthcare consulting and lobbying firm Leavitt Partners concludes.

“We found compelling

Read More »

340B Hospitals Use Biosimilars Less Than Others, PhRMA-Commissioned Study Finds

Biosimilar
340B hospitals use biosimilar drugs less than other hospitals, a PhRMA-funded study found.

340B hospitals use biosimilar drugs less than other hospitals, which may expose patients to higher out-of-pocket costs, a drug industry funded study concludes.

Pharmaceutical Research and Manufacturers of America released the study last week. Healthcare consulting firm Milliman did the

Read More »

Hospital Group Says Survey Shows Drug Companies’ 340B Contract Pharmacy Limits Are Harmful

AHA survey
Drug companies' 340B contract pharmacy limits are harming 340B hospitals and their patients, the AHA says a new member survey shows.

Drug company actions to limit 340B pricing through contract and specialty pharmacies are harming 340B hospitals and their patients, according to a new American Hospital Association member survey.  

AHA released the results yesterday. More than 300 hospitals were surveyed

Read More »

340B Law Should Be Amended to Include Emergency-Use COVID-19 Drugs, Health Affairs Opinion Article Says

Bebtelovimab
A screen shot from an HHS video about the monoclonal antibody betelovimab used to treat COVID-19 infection.

The 340B statute should be amended to extend discounts to emergency-use drugs to treat COVID-19 as a first step in rebuilding the COVID-19 safety net, an opinion piece published yesterday in the medical journal Health Affairs says.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report